| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
One-methyl-tryptophan, an IDO inhibitor, comes in two stereoisomers, each of which may have distinct pharmacological characteristics. In studies utilizing HeLa cells and the pure enzyme, the L isomer exhibits greater potency as an inhibitor of IDO activity. On the other hand, the inhibition of T cells caused by dendritic cells expressing IDO is considerably more effectively reversed by the D isomer. The competitive inhibitory action of 1-methyl-tryptophan was observed for the L isomer (Ki=19 μM), while the d isomer exhibited significantly lower efficacy. The DL combination has a Ki of 35 μM, making it intermediate[1].
|
||
|---|---|---|---|
| ln Vivo |
Tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer, the D isomer is more effective as an anticancer agent in chemo-immunotherapy regimens using NSC-26271, NSC 125973, or LY 188011. Since mice with an IDO gene disruption (IDO-knockout mice) completely lose the antitumor effect of d-1-methyl-tryptophan, the D isomer of 1-methyl-tryptophan specifically targets the IDO gene. When combined with NSC 125973, oral dl-1-methyl-tryptophan administration has been shown to cause autochthonous breast tumor regression[1].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Indoximod is an indolyl carboxylic acid.
Indoximod has been used in trials studying the treatment of Glioma, Melanoma, Ependymoma, Gliosarcoma, and Lung Cancer, among others. Indoximod is a methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. |
| Molecular Formula |
C12H14N2O2
|
|
|---|---|---|
| Molecular Weight |
218.25
|
|
| Exact Mass |
218.105
|
|
| CAS # |
110117-83-4
|
|
| Related CAS # |
(Rac)-Indoximod;26988-72-7;(S)-Indoximod;21339-55-9
|
|
| PubChem CID |
405012
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
429.3±35.0 °C at 760 mmHg
|
|
| Melting Point |
242-245 ℃(lit.)
|
|
| Flash Point |
213.4±25.9 °C
|
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
|
| Index of Refraction |
1.625
|
|
| LogP |
1.43
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
16
|
|
| Complexity |
270
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
CN1C=C(C2=CC=CC=C21)C[C@H](C(=O)O)N
|
|
| InChi Key |
ZADWXFSZEAPBJS-SNVBAGLBSA-N
|
|
| InChi Code |
InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
|
|
| Chemical Name |
(2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (4.58 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5819 mL | 22.9095 mL | 45.8190 mL | |
| 5 mM | 0.9164 mL | 4.5819 mL | 9.1638 mL | |
| 10 mM | 0.4582 mL | 2.2910 mL | 4.5819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01560923 | Completed Has Results | Biological: Indoximod Biological: Sipuleucel-T |
Metastatic Prostate Cancer | Masonic Cancer Center, University of Minnesota |
October 1, 2012 | Phase 2 |
| NCT02835729 | Completed | Drug: Cytarabine Drug: Indoximod Freebase |
Acute Myeloid Leukemia | NewLink Genetics Corporation | July 2016 | Phase 1 |
| NCT02502708 | Completed | Drug: Indoximod Drug: Temozolomide |
Glioblastoma Multiforme Glioma |
NewLink Genetics Corporation | October 2015 | Phase 1 |
| NCT02077881 | Completed | Drug: Gemcitabine Drug: Indoximod |
Metastatic Pancreatic Adenocarcinoma | NewLink Genetics Corporation | August 2014 | Phase 1 Phase 2 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
